Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Launched by EMORY UNIVERSITY · Aug 11, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called atovaquone to see if it can help treat women with a type of ovarian cancer known as platinum-resistant ovarian cancer. This type of cancer is defined as having worsened within six months after the last treatment that included platinum-based chemotherapy. Atovaquone is usually used to treat certain infections, but researchers are exploring whether it can also be effective in fighting this particular cancer. The trial is currently recruiting participants, and women between the ages of 65 and 74 who meet specific health criteria may be eligible to join.
To qualify, participants must have been diagnosed with high-grade serous ovarian cancer and must be in good enough health to perform daily activities. They can have received any number of previous treatments and can even be referred from their local doctors. If you join the trial, you can expect to receive atovaquone and be monitored for how well it works compared to standard chemotherapy. It’s important to note that this trial is not open to individuals under 18, pregnant or breastfeeding women, or those who cannot provide consent due to health reasons. Overall, this trial offers a potential new treatment option for those who have limited choices left for managing their cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
- • Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- • There will be no limitations on number of prior lines of therapy
- • Trial is open to non-English speaking patients
- • Trial is open to patients referred from community practice
- Exclusion Criteria:
- • Patients who are \< 18 years old
- • Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
- • Patients who are incarcerated
- • Patients who are unable to provide consent / lack decision-making capacity
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
Namita Khanna, MD, MSPH
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported